| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/08/2001 | WO2000058307A3 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 02/08/2001 | WO2000058295A3 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 02/08/2001 | WO2000056737A3 Calanolides for inhibiting btk |
| 02/08/2001 | WO2000048617A3 Connective tissue softening |
| 02/08/2001 | WO2000048446A3 Use of antagonists of pg-e for the treatment of neuropathic pain |
| 02/08/2001 | WO2000024365A8 Treatment of skin with adenosine or adenosine analog |
| 02/08/2001 | DE19935303A1 Oligonukleotide zur Inhibierung der Expression von humanem eg5 Oligonucleotides for inhibiting the expression of human Eg5 |
| 02/08/2001 | DE19935302A1 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen Conjugates and methods for their preparation and their use for transporting molecules across biological membranes |
| 02/08/2001 | DE19904800C1 Partikel zur Gentherapie Particles for gene therapy |
| 02/08/2001 | DE10020237A1 Verwendung von N-Anisoyl-gamma-aminobuttersäure oder p-Anissäure zur Herstellung einer pharmazeutichen Zusammensetzung Use of N-anisoyl gamma-aminobutyric acid or p-anisic acid for preparing a composition pharmazeutichen |
| 02/08/2001 | CA2697207A1 Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications |
| 02/08/2001 | CA2647796A1 Method of inhibiting osteoclast activity |
| 02/08/2001 | CA2391766A1 C-6 ring-substituted pyrido¬1,2-a|benzimidazole derivatives usefu l in treating central nervous system disorders |
| 02/08/2001 | CA2391348A1 Enhanced delivery via serpin enzyme complex receptor |
| 02/08/2001 | CA2391267A1 Chemokine receptor antagonists and methods of use therefor |
| 02/08/2001 | CA2388663A1 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 02/08/2001 | CA2388297A1 Ophthalmic compositions containing antibiotics and nsaids |
| 02/08/2001 | CA2380837A1 High affinity tgf.beta. nucleic acid ligands and inhibitors |
| 02/08/2001 | CA2380644A1 2-pyrazolin-5-ones |
| 02/08/2001 | CA2380631A1 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 02/08/2001 | CA2380608A1 Serotonergic benzofurans |
| 02/08/2001 | CA2380545A1 Nucleic acid ligands to cd40ligand |
| 02/08/2001 | CA2380531A1 Benzofurylpiperazine serotonin agonists |
| 02/08/2001 | CA2380428A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 02/08/2001 | CA2380032A1 Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 02/08/2001 | CA2380029A1 Benzenamine derivatives as anti-coagulants |
| 02/08/2001 | CA2380009A1 Methods of inhibiting osteoclastogenesis |
| 02/08/2001 | CA2380007A1 Methods of inhibiting osteoclast activity |
| 02/08/2001 | CA2379993A1 Acyclic and cyclic amine derivatives |
| 02/08/2001 | CA2379663A1 Cartilage or bone matrix as a nucleic acid delivery vehicle |
| 02/08/2001 | CA2379660A1 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 02/08/2001 | CA2378942A1 Imidazole antiproliferative agents |
| 02/08/2001 | CA2378929A1 Serine proteases |
| 02/08/2001 | CA2378878A1 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 02/08/2001 | CA2378710A1 Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |
| 02/08/2001 | CA2378331A1 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/08/2001 | CA2378176A1 Heterocyclic compounds inhibiting angiogenesis |
| 02/08/2001 | CA2376927A1 Oxazinocarbazoles for the treatment of cns diseases |
| 02/08/2001 | CA2346014A1 Implant attachement stabilizer |
| 02/08/2001 | CA2345753A1 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| 02/07/2001 | EP1074620A1 Monomeric protein of the TGF-beta family |
| 02/07/2001 | EP1074618A2 Cadherin materials and methods |
| 02/07/2001 | EP1074559A1 Peptide nucleic acids |
| 02/07/2001 | EP1074549A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| 02/07/2001 | EP1074542A1 Sulfonamide-containing indole compounds |
| 02/07/2001 | EP1074266A2 Live attenuated bacteria for use in a vaccine |
| 02/07/2001 | EP1074262A1 Laminaria algae extract, method of preparation and cosmetic or pharmaceutical compositions containing the same |
| 02/07/2001 | EP1074260A1 IL-12 Production inhibitor |
| 02/07/2001 | EP1074257A1 2,7-Substituted octahydro-1H-pyrido (1,2-A)pyrazine derivatives as ligands for serotonin receptors |
| 02/07/2001 | EP1074252A2 Composition comprising theanine for suppressing behaviour problems of pets |
| 02/07/2001 | EP1073764A1 Membrane-permeant phosphoinositides |
| 02/07/2001 | EP1073759A1 Recombinant virus expressing foreign dna encoding feline cd80, feline cd28, feline ctla-4 or feline cd86 and uses thereof |
| 02/07/2001 | EP1073758A1 Retroviral vectors including modified envelope escort proteins |
| 02/07/2001 | EP1073750A1 Preparation of human papillomavirus e1 having helicase activity and method therefor |
| 02/07/2001 | EP1073741A2 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides |
| 02/07/2001 | EP1073739A2 Cd40-interacting and traf-interacting proteins |
| 02/07/2001 | EP1073738A2 Human k+ ion channel and therapeutic applications thereof |
| 02/07/2001 | EP1073737A2 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 02/07/2001 | EP1073736A1 Delayed rectifier potassium channel subunit |
| 02/07/2001 | EP1073733A1 MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY |
| 02/07/2001 | EP1073683A1 G-csf receptor agonist antibodies and screening method therefor |
| 02/07/2001 | EP1073681A1 Cloning of a novel 7tm receptor axor-2 |
| 02/07/2001 | EP1073680A1 Protein mixtures to induce therapeutic angiogenesis |
| 02/07/2001 | EP1073666A1 Composition for treatment of external secretion disorders except hypolacrimation |
| 02/07/2001 | EP1073664A1 (alpha-aminophosphino) peptidesderivative and compositions containing same |
| 02/07/2001 | EP1073658A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| 02/07/2001 | EP1073651A1 Indolyl derivatives as serotonergic agents |
| 02/07/2001 | EP1073641A2 New substituted amides, their production and their use |
| 02/07/2001 | EP1073640A1 Naphthalene derivatives, their production and use |
| 02/07/2001 | EP1073639A1 Quinoline derivatives |
| 02/07/2001 | EP1073638A1 Heterocyclically substituted amides, their production and their use |
| 02/07/2001 | EP1073636A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists |
| 02/07/2001 | EP1073635A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| 02/07/2001 | EP1073632A1 Substituted benzamides, their production and their use as cysteine protease inhibitors |
| 02/07/2001 | EP1073631A1 New substituted amides, their production and their use |
| 02/07/2001 | EP1073467A2 Cosolvent formulations |
| 02/07/2001 | EP1073466A1 Solution containing nicotine |
| 02/07/2001 | EP1073465A1 T cell inhibitory receptor compositions and uses thereof |
| 02/07/2001 | EP1073457A1 Modifications of antigens by the introduction of aldehyde groups and their use in enhancing the immune response |
| 02/07/2001 | EP1073453A1 Methods to increase white blood cell survival after chemotherapy |
| 02/07/2001 | EP1073452A2 Method for treating cytokine mediated hepatic injury |
| 02/07/2001 | EP1073451A2 Method for treating ischemia |
| 02/07/2001 | EP1073448A1 Fertility improving composition and application thereof |
| 02/07/2001 | EP1073440A1 sPLA 2 INHIBITOR ESTER |
| 02/07/2001 | EP1073438A1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO 5,6]CYCLOHEPTA 1,2-b]PYRIDINE ORAL COMPOSITIONS |
| 02/07/2001 | EP1073435A1 Substituted tricyclic pyrazole derivatives with protein kinase activity |
| 02/07/2001 | EP1073434A1 Ccr-3 receptor antagonists |
| 02/07/2001 | EP1073431A1 Use of nmda antagonists for treatment of irritable bowel syndrome |
| 02/07/2001 | EP1073430A1 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders |
| 02/07/2001 | EP1073427A1 Periadventitial delivery device |
| 02/07/2001 | EP1073418A1 Aqueous composition comprising active ingredients for the de-pigmentation of the skin |
| 02/07/2001 | EP1073417A1 Pharmaceutical aerosol formulation |
| 02/07/2001 | EP1073334A1 Serotonin potentiation by oleamide analogs |
| 02/07/2001 | EP1033997A4 Method of mobilizing hematopoietic stem cells |
| 02/07/2001 | EP0799226B1 Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists |
| 02/07/2001 | EP0559769B1 Heparin binding mitogen with homology to epidermal growth factor (egf) |
| 02/07/2001 | CN1283224A Hyaluronan synthase gene and uses thereof |
| 02/07/2001 | CN1283192A Inhibition of raf kinase using aryl and hetroaryl substituted heterocyclic ureas |
| 02/07/2001 | CN1283188A Bisulfate salt of HIV protease inhibitor |
| 02/07/2001 | CN1283183A Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |